Linagliptin: the newest dipeptidyl peptidase-4 inhibitor for type 2 diabetes mellitus.
Aletti R, Cheng-Lai A.
Cardiol Rev · review; journal article · DOI 10.1097/crd.0b013e31823a3afc PUBLIKATIONSREGISTRET
Gå till forskningen.
Publikationsdata från Europe PMC och PubMed. Följ källhänvisningar från ämnesregistret till originalpublikationerna.
Publikationer som ChEBI hänvisar till för linagliptin. Visa hela publikationsregistret
En publikationsträff är inte en slutsats. Publikationslistan visar bibliografiska uppgifter. Eventuella forskningsutdrag visas separat med originalunderlag. En källhänvisning visar inte i sig effekt, dosering eller säkerhet.
Publikationer i urvalet
74 träffarLinagliptin, a dipeptidyl peptidase-4 inhibitor with a unique pharmacological profile, and efficacy in a broad range of patients with type 2 diabetes.
Forst T, Pfützner A.
Expert Opin Pharmacother · research support, non-u.s. gov't; review; journal article · DOI 10.1517/14656566.2012.642863Effects of the DPP-4 inhibitor, linagliptin, in diet-induced obese rats: a comparison in naive and exenatide-treated animals.
Vickers SP, Cheetham SC, Birmingham GD, Rowley HL, Headland KR, Dickinson K, Grempler R, Hocher B, Mark M, Klein T.
Clin Lab · research support, non-u.s. gov't; journal article · DOI 10.7754/clin.lab.2011.110919Excretion of the dipeptidyl peptidase-4 inhibitor linagliptin in rats is primarily by biliary excretion and P-gp-mediated efflux.
Fuchs H, Runge F, Held HD.
Eur J Pharm Sci · research support, non-u.s. gov't; journal article · DOI 10.1016/j.ejps.2011.11.018Efficacy and safety of linagliptin (tradjenta) in adults with type-2 diabetes mellitus.
Freeman MK.
P T · research-article; journal articleNovel heterocyclic DPP-4 inhibitors for the treatment of type 2 diabetes.
Sutton JM, Clark DE, Dunsdon SJ, Fenton G, Fillmore A, Harris NV, Higgs C, Hurley CA, Krintel SL, MacKenzie RE, Duttaroy A, Gangl E, Maniara W, Sedrani R, Namoto K, Ostermann N, Gerhartz B, Sirockin F, Trappe J, Hassiepen U, Baeschlin DK.
Bioorg Med Chem Lett · journal article · DOI 10.1016/j.bmcl.2011.11.054Efficacy and safety of linagliptin in persons with type 2 diabetes inadequately controlled by a combination of metformin and sulphonylurea: a 24-week randomized study.
Owens DR, Swallow R, Dugi KA, Woerle HJ.
Diabet Med · clinical trial, phase iii; multicenter study; randomized controlled trial; journal article · DOI 10.1111/j.1464-5491.2011.03387.xLinagliptin for the treatment of type 2 diabetes (pharmacokinetic evaluation).
Scheen AJ.
Expert Opin Drug Metab Toxicol · review; journal article · DOI 10.1517/17425255.2011.628986Effect of renal impairment on the pharmacokinetics of the dipeptidyl peptidase-4 inhibitor linagliptin(*).
Graefe-Mody U, Friedrich C, Port A, Ring A, Retlich S, Heise T, Halabi A, Woerle HJ.
Diabetes Obes Metab · research support, non-u.s. gov't; journal article · DOI 10.1111/j.1463-1326.2011.01458.xLinagliptin for the treatment of type 2 diabetes.
Del Prato S.
Expert Opin Pharmacother · comment; journal article · DOI 10.1517/14656566.2011.613825Linagliptin and newer DPP-4 inhibitors: newer uses and newer indications.
Kalra S, Unnikrishnan AG, Agrawal N, Singh AK.
Recent Pat Endocr Metab Immune Drug Discov · journal article · DOI 10.2174/187221411797265926Linagliptin: a novel xanthine-based dipeptidyl peptidase-4 inhibitor for treatment of type II diabetes mellitus.
Ghatak SB, Patel DS, Shanker N, Srivastava A, Deshpande SS, Panchal SJ.
Curr Diabetes Rev · review; journal article · DOI 10.2174/157339911797415648A randomized, open-label, crossover study evaluating the effect of food on the relative bioavailability of linagliptin in healthy subjects.
Graefe-Mody U, Giessmann T, Ring A, Ring A, Iovino M, Woerle HJ.
Clin Ther · research support, non-u.s. gov't; randomized controlled trial; journal article · DOI 10.1016/j.clinthera.2011.07.005Pharmacokinetic, pharmacodynamic, and tolerability profiles of the dipeptidyl peptidase-4 inhibitor linagliptin: a 4-week multicenter, randomized, double-blind, placebo-controlled phase IIa study in Japanese type 2 diabetes patients.
Horie Y, Kanada S, Watada H, Sarashina A, Taniguchi A, Hayashi N, Graefe-Mody EU, Woerle HJ, Dugi KA.
Clin Ther · clinical trial, phase ii; research support, non-u.s. gov't; multicenter study; randomized controlled trial; journal article · DOI 10.1016/j.clinthera.2011.06.005The DPP-4 inhibitor linagliptin does not prolong the QT interval at therapeutic and supratherapeutic doses.
Ring A, Port A, Graefe-Mody EU, Revollo I, Iovino M, Dugi KA.
Br J Clin Pharmacol · research-article; randomized controlled trial; journal article · DOI 10.1111/j.1365-2125.2011.03931.xEfficacy and safety of initial combination therapy with linagliptin and pioglitazone in patients with inadequately controlled type 2 diabetes: a randomized, double-blind, placebo-controlled study.
Gomis R, Espadero RM, Jones R, Woerle HJ, Dugi KA.
Diabetes Obes Metab · research support, non-u.s. gov't; multicenter study; randomized controlled trial; journal article · DOI 10.1111/j.1463-1326.2011.01391.xLinagliptin: a new DPP-4 inhibitor for the treatment of type 2 diabetes mellitus.
Toth PP.
Postgrad Med · research support, non-u.s. gov't; review; journal article · DOI 10.3810/pgm.2011.07.2303Review of the safety and efficacy of linagliptin as add-on therapy to metformin in patients with type 2 diabetes: a randomized, double-blind, placebo-controlled study.
Rendell M, Chrysant SG.
Postgrad Med · comment; journal article · DOI 10.3810/pgm.2011.07.2318Vilazodone hydrochloride, linagliptin, and alcaftadine.
Hussar DA, Samuel J.
J Am Pharm Assoc (2003) · journal article · DOI 10.1331/japha.2011.11534The oral DPP-4 inhibitor linagliptin significantly lowers HbA1c after 4 weeks of treatment in patients with type 2 diabetes mellitus.
Forst T, Uhlig-Laske B, Ring A, Ring A, Ritzhaupt A, Graefe-Mody U, Dugi KA.
Diabetes Obes Metab · clinical trial, phase ii; research support, non-u.s. gov't; randomized controlled trial; journal article · DOI 10.1111/j.1463-1326.2011.01386.xLinagliptin approved for type 2 diabetes.
Traynor K.
Am J Health Syst Pharm · news · DOI 10.2146/news110038Linagliptin (Tradjenta)--a new DPP-4 inhibitor for type 2 diabetes.
Författaruppgift saknas
Med Lett Drugs Ther · review; journal articleLinagliptin: a novel dipeptidyl peptidase 4 inhibitor with a unique place in therapy.
Barnett AH.
Adv Ther · research support, non-u.s. gov't; review; journal article · DOI 10.1007/s12325-011-0028-yEffect of linagliptin on the pharmacokinetics and pharmacodynamics of warfarin in healthy volunteers.
Graefe-Mody EU, Brand T, Ring A, Ring A, Withopf B, Stangier J, Iovino M, Woerle HJ.
Int J Clin Pharmacol Ther · research support, non-u.s. gov't; journal article · DOI 10.5414/cp201507Effect of linagliptin monotherapy on glycaemic control and markers of β-cell function in patients with inadequately controlled type 2 diabetes: a randomized controlled trial.
Del Prato S, Barnett AH, Huisman H, Neubacher D, Woerle HJ, Dugi KA.
Diabetes Obes Metab · clinical trial, phase iii; research support, non-u.s. gov't; multicenter study; randomized controlled trial; journal article · DOI 10.1111/j.1463-1326.2010.01350.xLinagliptin: in type 2 diabetes mellitus.
Scott LJ.
Drugs · review; journal article · DOI 10.2165/11207400-000000000-00000Evaluation of the pharmacokinetic interaction after multiple oral doses of linagliptin and digoxin in healthy volunteers.
Friedrich C, Ring A, Ring A, Brand T, Sennewald R, Graefe-Mody EU, Woerle HJ.
Eur J Drug Metab Pharmacokinet · research support, non-u.s. gov't; randomized controlled trial; journal article · DOI 10.1007/s13318-011-0028-ySafety and efficacy of linagliptin as add-on therapy to metformin in patients with type 2 diabetes: a randomized, double-blind, placebo-controlled study.
Taskinen MR, Rosenstock J, Tamminen I, Kubiak R, Patel S, Dugi KA, Woerle HJ.
Diabetes Obes Metab · clinical trial, phase iii; research support, non-u.s. gov't; multicenter study; randomized controlled trial; journal article · DOI 10.1111/j.1463-1326.2010.01326.xEffect of multiple oral doses of linagliptin on the steady-state pharmacokinetics of a combination oral contraceptive in healthy female adults: an open-label, two-period, fixed-sequence, multiple-dose study.
Friedrich C, Port A, Ring A, Ring A, Graefe-Mody U, Giessmann T, Iovino M, Woerle HJ.
Clin Drug Investig · clinical trial; research support, non-u.s. gov't; journal article · DOI 10.2165/11590240-000000000-00000Pharmacokinetics and pharmacodynamics of single rising intravenous doses (0.5 mg-10 mg) and determination of absolute bioavailability of the dipeptidyl peptidase-4 inhibitor linagliptin (BI 1356) in healthy male subjects.
Retlich S, Duval V, Ring A, Ring A, Staab A, Hüttner S, Jungnik A, Jaehde U, Dugi KA, Graefe-Mody U.
Clin Pharmacokinet · comparative study; research support, non-u.s. gov't; randomized controlled trial; journal article · DOI 10.2165/11536620-000000000-00000